{
    "clinical_study": {
        "@rank": "141293", 
        "arm_group": {
            "arm_group_label": "treatment group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To assess the effect of multiple doses of mirabegron to postmenopausal adult female subjects\n      on the pharmacokinetics (PK) of tolterodine and its metabolites.\n\n      In addition, the safety of these products will be assessed."
        }, 
        "brief_title": "Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pharmacokinetics of Mirabegron and Tolterodine", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects of two years after menopause\n\n          -  Body weight (at screening) \u2265 40.0 kg and < 70.0 kg\n\n          -  Body mass index (BMI) (at screening) \u2265 17.6 kg/m2 and < 26.4 kg/m2\n\n          -  Healthy, as judged by the investigator/sub-investigator based on medical history and\n             the results of physical examination (subjective symptoms and objective findings) and\n             all tests obtained at screening and during the period from hospital admission (at\n             single dosing phase) to immediately before study medication.\n\n        Exclusion Criteria:\n\n          -  Received or scheduled to receive any investigational drugs in other clinical trials,\n             post-marketing studies, or clinical studies within 120 days before the screening or\n             during the period from the screening to hospitalization (Day \u22122).\n\n          -  Donated or scheduled to donate 400 mL of whole blood within 90 days before the\n             screening or during the period from the screening to hospitalization (Day \u22122), 200 mL\n             of whole blood within 30 days before the screening or during the period from the\n             screening to hospitalization (Day \u22122), or blood components within 14 days before the\n             screening or during the period from the screening to hospitalization (Day \u22122).\n\n          -  Any deviation of the laboratory tests at screening or hospitalization (Day \u22122).\n\n          -  A deviation from the normal range of blood pressure, pulse rae, or body temperature\n             at screening or hospitalization (Day -2) Supine blood pressure: Systolic blood\n             pressure: \u226590 mmHg, \u2264140 mmHg, Diastolic blood pressure: \u226540 mmHg, \u226490 mmHg Supine\n             pulse rate;  \u226540 bpm, \u226499 bpm Axillary body temperature;  \u226535.0\u00b0C, \u226437.0\u00b0C\n\n          -  History of drug allergies\n\n          -  Upper gastrointestinal disease (e.g., nausea, vomiting, and stomachache) within 7\n             days before hospitalization (Day \u22122)\n\n          -  Concurrent or previous hepatic disease (e.g., viral hepatitis, drug-induced liver\n             injury, and hepatic impairment)\n\n          -  Concurrent or previous heart disease (e.g., congestive heart failure, angina\n             pectoris, and arrhythmia requiring treatment)\n\n          -  Concurrent or previous GI disease (e.g., ileus paralytic, gastric atony, intestinal\n             atony, colitis ulcerative, peptic ulcer and gastroesophageal reflux esophagitis;\n             except for a history of appendicitis).\n\n          -  Concurrent or previous renal disease (e.g., acute renal failure, glomerulonephritis,\n             and interstitial nephritis)\n\n          -  Concurrent or previous endocrine disease (e.g., hyperthyroidism and blood growth\n             hormone abnormal)\n\n          -  Concurrent or previous cerebrovascular disorder (e.g., cerebral infarction)\n\n          -  Previous use of mirabegron or tolterodine\n\n          -  Excessive smoking or drinking habit"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964183", 
            "org_study_id": "178-CL-111"
        }, 
        "intervention": [
            {
                "arm_group_label": "treatment group", 
                "description": "Oral", 
                "intervention_name": "tolterodine", 
                "intervention_type": "Drug", 
                "other_name": "Detrusitol\u00ae Capsules"
            }, 
            {
                "arm_group_label": "treatment group", 
                "description": "Oral", 
                "intervention_name": "mirabegron", 
                "intervention_type": "Drug", 
                "other_name": [
                    "YM178", 
                    "Betanis\u00ae tablets"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tolterodine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Open-label design", 
            "Pharmacokinetics", 
            "Drug-Drug Interaction", 
            "Mirabegron"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanto", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Post-Marketing Study of Mirabegron - A Pharmacokinetic Study to Assess Drug-Drug Interaction Between Mirabegron and Tolterodine -", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Plasma concentration of unchanged mirabegron", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Plasma concentration of unchanged tolterodine", 
                "safety_issue": "No", 
                "time_frame": "Day 7, Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964183"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentration of tolterodine metabolites (5-hydroxymethyl tolterodine; 5-HMT)", 
                "safety_issue": "No", 
                "time_frame": "Day 7, Day 14"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, clinical labo-tests, and 12-lead ECG", 
                "safety_issue": "No", 
                "time_frame": "Day -2, Day 8, Day 15, Day 22"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}